Sign up online today & collaborate
or click here to find out more
Adaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct Offering10/04/2017Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced registered direct offering of its American Depositary Shares (“ADSs”) following its entry into a definitive agreement with Matrix Capital Management Company, LP (“Matrix”) to purchase an aggregate of approx
Consilium Strategic Communications and Westwicke Partners Enter into Joint Venture for Healthcare Focused US IR Advisory10/04/2017Consilium Strategic Communications, a global leader in strategic healthcare communications, today announces a joint venture with Westwicke Partners, the largest independent healthcare-focused investor relations and capital markets advisory firm in the US.Consilium and Westwicke already support a number of shared clients and the new joint venture will see the two teams
Endo International plc Announces Pricing of Private Offering of Senior Secured Notes12/04/2017Endo International plc (NASDAQ: ENDP) ("Endo") today announced that Endo Designated Activity Company, Endo Finance LLC and Endo Finco Inc. (collectively, the "Issuers"), its wholly-owned subsidiaries, priced $300 million aggregate principal amount of 5.875% senior secured notes due 2024 at an issue price of $1000 per $1000 principal amount in connection with their previously announced private offering.
Disruption is the new normal 03/05/2017We live in an age of change where technology is allowing markets to move with breathtaking speed. Radical disruption is now a given. Companies that fail to expect and embrace it are left behind. Global brands that have grown spectacularly in recent years – such as AirBnB and Uber – have come from nowhere to transform entire sectors with their revolutionary approaches. Their ability to innovate – in terms of both products and the busin
Summit Therapeutics plc: Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases 05/05/2017Summit Therapeutics plc: Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases Summit Therapeutics plc('Summit', or the 'Company')PHASE 2 CoDIFy TRIAL RESULTS PUBLISHED IN LANCET INFECTIOUS DISEASES WITH DATA SHOWING SUMMIT'S RIDINILAZOLE ACHIEVED STATISTICAL SUPERIORITY OVER VANCOMYCIN IN THE TREATMENT OF C. DIFFICILE INFECTIONOxford, UK, 2 May 201